Evidence map›Paper›PMID 31095598›Full record

Trial reportPloS one2019

Intermediate-onset colorectal cancer: A clinical and familial boundary between both early and late-onset colorectal cancer.

María Arriba, Carmen Sánchez, Alfredo Vivas, O A Nutu, Daniel Rueda, Sandra Tapial, Yolanda Rodríguez, Lorena Brandáriz, Juan L García, Damián García-Olmo and 4 more

Abstract readClinical Trial
In one paragraph

Trial report in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. RecurrentCancers · 2022
    Article
  6. Article
  7. Observational
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

María ArribaDepartment of Clinical Biochemistry, "Gregorio Marañón" University Hospital, Madrid, Spain.ORCID 0000-0001-6516-643X
Carmen SánchezDepartment of Surgery, "12 de Octubre" University Hospital, Madrid, Spain.
Alfredo VivasDepartment of Surgery, "12 de Octubre" University Hospital, Madrid, Spain.
O A NutuDepartment of Surgery, "12 de Octubre" University Hospital, Madrid, Spain.
Daniel RuedaMolecular Biology Laboratory, "12 de Octubre" University Hospital, Madrid, Spain.
Sandra TapialCentre for Biomedical Research of "12 de Octubre" University Hospital, Madrid, Spain.
Yolanda RodríguezDepartment of Pathology, "12 de Octubre" University Hospital, Madrid, Spain.
Lorena BrandárizDepartment of Surgery, "Fundación Jiménez Díaz" University Hospital, Madrid, Spain.
Juan L GarcíaMolecular Medicine Unit, Department of Medicine, Institute of Molecular and Cellular Biology of Cancer (IBMCC) and Biomedical Research Institute of Salamanca (IBSAL), University of Salamanca-SACYL-CSIC, Salamanca, Spain.
Damián García-OlmoDepartment of Surgery, "Fundación Jiménez Díaz" University Hospital, Madrid, Spain.
Ajay GoelCenter for Gastrointestinal Research, Center for Translational Genomics and Oncology, Baylor Scott & White Research Institute, Charles A, Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas, United States of America.
Rogelio González-SarmientoMolecular Medicine Unit, Department of Medicine, Institute of Molecular and Cellular Biology of Cancer (IBMCC) and Biomedical Research Institute of Salamanca (IBSAL), University of Salamanca-SACYL-CSIC, Salamanca, Spain.
Miguel UriosteCentre for Biomedical Network Research on Rare Diseases (CIBERER), Institute of Health Carlos III, Madrid, Spain.
José PereaDepartment of Surgery, "Fundación Jiménez Díaz" University Hospital, Madrid, Spain.ORCID 0000-0001-5522-8844

Funding

The Biology and Diagnosis of HNPCCR01CA072851 · NCI · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI GOEL, AJAY · 1996 to 2019
$6.6M
Aspirin and Cancer Prevention in Lynch Syndrome: From Cell to Population DataU01CA187956 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI GOEL, AJAY, WODARZ, DOMINIK F · 2014 to 2018
$2.7M
MicroRNA Biomarkers for Determining Treatment Response in Colorectal CancerR01CA202797 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI GOEL, AJAY · 2016 to 2020
$1.9M
Development of microRNA Biomarkers For Noninvasive Detection of Colorectal CancerR01CA184792 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI GOEL, AJAY · 2015 to 2019
$1.8M
METHYLATION BIOMARKER DEVELOPMENT FOR NONINVASIVE DETECTION OF COLORECTAL CANCERR01CA181572 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI GOEL, AJAY · 2014 to 2018
$1.6M
NCI NIH HHS R01 CA072851NCI NIH HHS R01 CA181572NCI NIH HHS R01 CA184792NCI NIH HHS R01 CA202797NCI NIH HHS U01 CA187956
6 · The paper itself

Abstract

Comparative studies of colorectal cancer (CRC) according to the age of onset have found differences between early-onset CRC (EOCRC) and late-onset CRC (LOCRC). Using this as a starting point, we wished to determine whether intermediate-onset CRC (IOCRC) might also be considered as an independent group within CRC. We performed a retrospective comparative study of the clinicopathological and familial features, as well as of the symptoms and their duration, of a total of 272 subjects diagnosed with CRC classified into three groups according to the age-of-onset (98 EOCRC, 83 IOCRC and 91 LOCRC). The results show that from a clinicopathological point of view, IOCRC shared certain features with EOCRC (gender, prognosis), and with LOCRC (multiple primary CRCs), whereas it also had characteristics that were specific for IOCRC (mean number of associated polyps). A gradual progression was observed from EOCRC to LOCRC from a greater family aggregation to sporadic cases, in parallel with a change of Lynch Syndrome cases to the sporadic microsatellite instability pathway, with the IOCRC being a boundary group that is more related to EOCRC. With respect to symptoms, duration and correlation with stages, IOCRC appeared more similar to EOCRC. Clinically, IOCRC behaves as a transitional group between EOCRC and LOCRC, with features in common with both groups, but also with IOCRC-specific features. Excluding cases with familial cancer history, the awareness for EOCRC diagnosis should be extended to IOCRC.

Indexed as

Colonic NeoplasmsColorectal Neoplasms, Hereditary NonpolyposisMicrosatellite InstabilityAdultAgedAge of OnsetDisease-Free SurvivalFemaleHumansMaleMiddle AgedSurvival Rate

Identifiers

PMID31095598
PMCPMC6521992

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.